APP and Alzheimer disease: Therefore, future studies need to accurately simulate the molecular and pathological characteristics of clinical AD through genetic modification based on transgenic animal models, such as APP/PS1, to provide more reliable experimental evidence for the clinical translation of KSG (Long et al., 2024; Toledano et al., 2024).